Retatrutide, an investigational weight-loss drug, is drawing global attention after early clinical results showed substantial weight reduction. What makes it stand out is its “triple-action” approach, targeting three hormone receptors involved in metabolism. Researchers are also exploring whether it could support broader longevity goals, potentially offering new options for obesity and related diabetes.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
